An observational study in ALS, sponsored by Seoul National University Bundang Hospital. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-07-16.
Sponsored by Seoul National University Bundang Hospital · Observational
This is a retrospective cohort study to assess the factor associated with success of non-invasive positive ventilation in ALS patients.
Patients with ALS who were admitted to a tertiary hospital for initially applying non-invasive positive pressure ventilation (NIPPV). The objective of this study was to investigate factors associated with optimal NIPPV initiation and adherence, and to assess the long-term effects of NIPPV adherence in ALS patients.
1,000 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 284 are open to participants now.
This study's enrollment of 51 is below the median of 103 across 272 observational studies indexed under Amyotrophic Lateral Sclerosis.
Browse Amyotrophic Lateral Sclerosis studies →Seoul National University Bundang Hospital is the lead sponsor of 376 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
ALS patients who were admitted for applying non-invasive positive pressure ventilation initially.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Success of NIPPV
The success of NIPPV application was defined empirically as use of ≥ 2 hours per day and the failure as use of \< 2 hours for a day or conversion to invasive positive pressure ventilation via tracheostomy or refuse to apply NIPPV during hospitalization.
Time frame: through intervention completion, with an average of 10 days
Lenght of stay
The length of stay (LOS) was defined as the interval between admission and hospital discharge, and calculated as the number of midnights between admission and discharge from the hospital.
Time frame: through intervention completion, with an average of 10 days
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Oct 2022, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Seoul National University Bundang Hospital →